Joe Whalen joins Immedica’s Business development team
Stockholm, September 24, 2024 – Immedica is excited to announce that Joe Whalen has joined its business development team. Joe brings over a decade of experience from Horizon Therapeutics, where he was instrumental in growing the company from 20 employees with no sales to $3.6 billion in net sales and over 2,000 employees. Most recently, as Senior Vice President, Alliances & Business Development at Amgen, Joe played a key role in integrating Horizon following its $28 billion acquisition in 2023.
At Horizon from 2010-2023, Joe was pivotal in driving the company's strategic transactions. In his role at Immedica, he will focus on business development initiatives primarily in the U.S., operating part-time under a consultancy agreement from his base in the greater Chicago area. He will report directly to Immedica’s Head of Business Development.
"We are thrilled to have Joe on board," said Anders Edvell, CEO at Immedica. "Joe´s vast industry knowledge and successful track record in strategic deal-making will be key as we continue to drive growth and expand Immedica’s footprint in the rare disease and specialty care sectors."
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018 and employs today more than 120 people across Europe, the Middle East and the U.S. The main owners are the investment firms KKR and Impilo.
For more information visit www.immedica.com
Immedica contact:
Linda Holmström
Global Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95
Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm